What the Research Says About BPC-157 Understanding the current state of BPC-157 research helps set realistic expectations
Palchesko RN, Romeo JD, McGowan KA, Gawalt ES
Many practitioners recommend supplementing with oral methylcobalamin or sublingual B12 in addition to the compound, particularly for patients who have been on therapy for more than six months or who have documented low B12 levels
Is IV hydration better than oral hydration
Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated. Lee & Burgess, Alternative Therapies in Health and Medicine, 2025 Limitations : Only 2 participants Very short observation period No long-term follow-up No efficacy endpoints What These Studies Tell UsAnd What They Dont What We Can Reasonably Conclude Short-term tolerance appears acceptable : Across all three studies (roughly 30 participants total), no adverse events were reported
Cutting straight to the user question: Yes, BPC157 can be a risk, but the size of that risk depends on three things: 1
